Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy doubled in the fourth quarter, but the Danish pharmaceutical giant warns that sales growth for all its drugs — including Ozempic — is expected to slow in the coming year.
Read more...
Read More Details
Finally We wish PressBee provided you with enough information of ( The Ozempic boom is slowing down )
Also on site :
- Trump economic advisor confident in China trade deal conclusion on Monday
- Trump announces U.S.-China trade talks in London
- China consumer prices slump again, deepening deflation worries as demand stays weak